BALI MURALIDHAR

Bali Muralidhar serves as a Managing Partner at Abingworth, a globally recognized life sciences venture capital firm. In this pivotal role, she is instrumental in identifying and nurturing groundbreaking companies within the biotechnology and pharmaceutical sectors. Her leadership contributes significantly to Abingworth's mission of investing in and building innovative life science businesses that address critical unmet medical needs.

Muralidhar's investment focus at Abingworth spans venture and growth equity opportunities, with a particular emphasis on drug discovery and clinical development. She actively seeks out companies poised to make a substantial impact on patient care, evaluating potential across diverse therapeutic areas. Her strategic insights help portfolio companies navigate complex development pathways, from preclinical stages through clinical trials and commercialization. Bali Muralidhar's commitment to fostering innovation is evident in her approach to partnering with entrepreneurs and scientific founders, providing not just capital but also strategic guidance and operational support.

Before joining Abingworth, Bali Muralidhar built an impressive career marked by extensive experience in both venture capital and the pharmaceutical industry. Her background includes significant tenures at other leading life sciences investment firms, such as SV Health Investors, where she honed her expertise in identifying high-potential biotech assets. Prior to her venture capital career, she held key roles within the pharmaceutical industry, including at GlaxoSmithKline (GSK). This dual perspective, combining deep industry knowledge with a keen investment acumen, provides her with a unique advantage in evaluating opportunities and guiding portfolio companies towards success. Her comprehensive understanding of drug development, regulatory landscapes, and commercialization strategies is invaluable to the companies she supports.

Throughout her career, Bali Muralidhar has been involved in numerous successful investments, often serving on the boards of directors for Abingworth's portfolio companies. Her board roles allow her to provide hands-on strategic oversight, helping these companies achieve their scientific and business objectives. She is known for her rigorous due diligence, her ability to forge strong relationships with management teams, and her dedication to advancing novel therapies that can transform patient lives. Her contributions have helped drive significant value creation and bring important new medicines closer to patients.

As a Managing Partner, Bali Muralidhar continues to be a driving force behind Abingworth's investment strategy and its reputation as a leader in life sciences venture capital. Her expertise, leadership, and unwavering commitment to innovation are central to Abingworth's success in shaping the future of healthcare through strategic investment.